To evaluate the safety, tolerability, and preliminary efficacy of 9MW2821 in combination with other anti-tumor agents in patients with advanced gynecological malignancies.
Competent to comprehend, sign, and date an independent ethics committee/institutional review board/research ethics board (IEC/IRB/REB) approved informed consent form.
Female subjects aged 18 to 75 years (including 18 and 75 years).
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Histopathological diagnosed of advanced gynecological tumors.
History of another malignancy within 3 years before the first dose of study drug.
Patients with ongoing clinically significant toxicities related to prior treatment.
Presence of Grade ≥ 2 peripheral neuropathy.
Exclusion of prior diseases and prior treatments as specified in the protocol.